CN111991417A - 一种具有生理响应性的次氯酸凝胶及其在皮肤创面中的应用 - Google Patents
一种具有生理响应性的次氯酸凝胶及其在皮肤创面中的应用 Download PDFInfo
- Publication number
- CN111991417A CN111991417A CN202011070468.XA CN202011070468A CN111991417A CN 111991417 A CN111991417 A CN 111991417A CN 202011070468 A CN202011070468 A CN 202011070468A CN 111991417 A CN111991417 A CN 111991417A
- Authority
- CN
- China
- Prior art keywords
- hypochlorous acid
- acid gel
- gel
- physiologically responsive
- poloxamer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 title claims abstract description 31
- 230000004043 responsiveness Effects 0.000 title claims abstract description 12
- 206010072170 Skin wound Diseases 0.000 title claims abstract description 9
- 239000011159 matrix material Substances 0.000 claims abstract description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 8
- 230000003385 bacteriostatic effect Effects 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 6
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 5
- 229920001993 poloxamer 188 Polymers 0.000 claims description 5
- 229940044519 poloxamer 188 Drugs 0.000 claims description 5
- 229920001992 poloxamer 407 Polymers 0.000 claims description 5
- 229940044476 poloxamer 407 Drugs 0.000 claims description 5
- 239000008213 purified water Substances 0.000 claims description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical class CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 3
- 229920002674 hyaluronan Polymers 0.000 claims description 3
- 229960003160 hyaluronic acid Drugs 0.000 claims description 3
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 3
- 239000002504 physiological saline solution Substances 0.000 claims description 3
- 239000008215 water for injection Substances 0.000 claims description 3
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 229920006037 cross link polymer Polymers 0.000 claims description 2
- 239000003906 humectant Substances 0.000 claims description 2
- 229940014041 hyaluronate Drugs 0.000 claims description 2
- -1 hyaluronic acid ester Chemical class 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 239000006174 pH buffer Substances 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000001103 potassium chloride Substances 0.000 claims description 2
- 235000011164 potassium chloride Nutrition 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000000375 suspending agent Substances 0.000 claims description 2
- 230000037314 wound repair Effects 0.000 claims description 2
- 239000004034 viscosity adjusting agent Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 abstract description 18
- 230000029663 wound healing Effects 0.000 abstract description 6
- 241000894006 Bacteria Species 0.000 abstract description 5
- 239000000017 hydrogel Substances 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000011149 active material Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 description 22
- 208000027418 Wounds and injury Diseases 0.000 description 22
- 241000700159 Rattus Species 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 5
- 206010040943 Skin Ulcer Diseases 0.000 description 4
- 239000000645 desinfectant Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 231100000019 skin ulcer Toxicity 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 206010062255 Soft tissue infection Diseases 0.000 description 2
- 206010048038 Wound infection Diseases 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000035617 depilation Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 208000008960 Diabetic foot Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010016936 Folliculitis Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 239000011557 critical solution Substances 0.000 description 1
- ZXJXZNDDNMQXFV-UHFFFAOYSA-M crystal violet Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1[C+](C=1C=CC(=CC=1)N(C)C)C1=CC=C(N(C)C)C=C1 ZXJXZNDDNMQXFV-UHFFFAOYSA-M 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229960001235 gentian violet Drugs 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 206010025226 lymphangitis Diseases 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 229910052979 sodium sulfide Inorganic materials 0.000 description 1
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种具有生理响应性的次氯酸凝胶及其在皮肤创面中的应用,属于医疗器械技术领域。将具有抑菌和促创面愈合等功能的活性成分加入到温敏性无菌水凝胶基质中,在室温条件下为流动性良好的溶胶态,在生理温度下迅速胶凝固化,完成对皮肤创面的物理隔绝,同时发挥生理活性材料功能,促进创面快速愈合。
Description
技术领域
本发明属于医疗器械领域,涉及一种具有生理响应性的次氯酸凝胶及其在皮肤创面中的应用。
皮肤及软组织感染是临床常见的感染类型之一,是由条件致病菌侵犯表皮、真皮和皮下组织引起的局部炎症性疾病,临床上比较常见,其包括毛囊炎、疖、痈、淋巴管炎、急性蜂窝织炎、烧伤创面感染、手术切口感染、褥疮感染以及糖尿病足等。另外早期及时预防和控制感染同样是创面规范处理的重要目标。目前治疗皮肤软组织或伤口感染,临床上主要应用抗生素类药物或者是消毒防腐剂如碘伏等,但是碘伏应用的效果并不理想,抗菌药物局部给药可促使伤口愈合,防止感染蔓延。而抗生素类药物副作用大,并且越来越多的细菌对传统杀菌药物有了抗药性。温敏水凝胶敷料具有对温度敏感的温敏基团,其具有最低临界共溶温度(LCST),在LCST附近体积会突然收缩或膨胀,发生溶胶相到收缩相的体积转变,即液态和固态的转化。在低温下为液态,作用在人体创面部位时即由液态转变为凝胶态,覆盖在创面部位,保持创面湿润,加快创面愈合。因此,与传统敷料相比,温敏性凝胶具有以下特点:①提供湿润环境,维持电解质平衡,加快伤口愈合;②负载抗菌成分,抑制创面微生物感染;③抵御外界刺激,防止伤口二度感染。
发明内容
为了克服上述现有技术的缺点,本发明的目的在于提供一种具有生理响应性的次氯酸凝胶及其在皮肤创面中的应用,该生理响应温敏次氯酸凝胶无毒性,安全性好。
为了达到上述目的,本发明采用以下技术方案予以实现:
a)创面修复材料,透明质酸钠和/或透明质酸衍生物;
b)抑菌成分,次氯酸和/或次氯酸盐;
c)温敏性基质材料,由泊洛沙姆407和/或泊洛沙姆188组成;
d)pH缓冲剂包括氯化钠、氯化钾、硫酸、盐酸、磷酸、磷酸盐或其他可溶性盐;
e)溶剂,纯化水。
所述的具有生理响应性的次氯酸凝胶中,透明质酸钠的质量浓度(w/v)≤1%,泊洛沙姆407的质量浓度(w/v)为17%~21%,泊洛沙姆188的质量浓度(w/v)为1%-3%,次氯酸的质量浓度(w/v)为0.01%-0-2.00%。
优选地,所述的具有生理响应性的壳聚糖凝胶中还添加药剂学上可接受的药用辅料。
进一步优选地,所述药用辅料包括黏度调节剂、助悬剂、抗氧剂、稳定剂和保湿剂中的一种或几种。
优选地,所述水为注射用水、生理盐水或纯化水。
优选地,所述透明质酸钠衍生物为透明质酸钠交联聚合物、透明质酸酯或透明质酸金属盐。
优选地,所述具有生理响应性的次氯酸凝胶的胶凝温度在30-37℃之间。
上述具有生理响应性的次氯酸凝胶的制备方法如下:
在低于28℃,洁净环境中将泊洛沙姆407和/或泊洛沙姆188置于生理盐水、注射用水或纯化水中,搅拌至完全溶胀;加入透明质酸和或其衍生物,充分混合均匀;加入次氯酸和/或次氯酸钠,用盐酸调节体系pH,得到具有生理响应性的次氯酸凝胶。
本发明上述用于皮肤创面的温敏凝胶系统,在室温(低于28℃)状态下以溶胶态通过喷雾瓶均匀地喷洒在创面处,在体温作用下,溶胶迅速完成相转变形成凝胶,能够有效抑制创面病原微生物增殖,抵御外界病原体的入侵,同时形成湿润的创伤环境,促进创面愈合。
具体实施方式
现结合实施例,对本发明作详细阐述,下述实施例是说明性的,不是限定性的,不能以下述说明限定本发明的保护范围。
实施例1:
该实施例展示本发明所含下列物质:
组分浓度(质量百分比)
经上述处方配置成溶液后,其pH值应在3-7;有效氯应在90-200mg/L。
实施例2:
该实施例展示本发明所含下列物质:
组分浓度(质量百分比)
经上述处方配置成溶液后,其pH值应在3-7;有效氯应在90-200mg/L。
实施例3:
该实施例展示本发明所含下列物质:
组分浓度(质量百分比)
经上述处方配置成溶液后,其pH值应在3-7;有效氯应在90-200mg/L。
实施例4:
抑菌效果检测实验
将金葡菌9h肉汤培养物制成菌悬液,取被试样液(实施例1、2、3、市售次氯酸消毒剂)和PBS(5mL)各3管。取上述菌悬液,分别在每个被试样液和对照样液内滴加100μL,混合均匀。开始计时,作用20min,分别取样液(0.5mL)投入含5mL PBS的试管内,充分混匀,作适当稀释,然后取其中2~3个稀释度,分别吸取1ml,置于3个平皿,用凉至40~45℃的营养琼脂培养基15mL作倾注,转动平皿,使其充分均匀,琼脂凝固后翻转平板,37℃培养48h,作活菌菌落计数,试验重复3次,计算抑菌率,见下表1:
表1实施例1、2、3抑菌率比较
样品类型 | 抑菌率(%) |
5mL PBS | 0 |
实施例1 | 90.8 |
实施例2 | 91.0 |
实施例3 | 93.0 |
市售次氯酸消毒剂 | 85.0 |
由表1中结果表明实施例1、2、3的抑菌水平高于市售次氯酸消毒剂,具有较强的抑菌效果,对伤口处细菌杀伤能力较强。
实施例5:次氯酸温敏凝胶促进创面愈合实验
1.大鼠创面模型建立
实验前均普通饲料喂养3天,自由摄食和饮水,室温为(22±1)℃,相对湿度40-70%;在大鼠禁食不禁水12h(最好24h)后,用10%水合氯醛按0.4ml/100g体重腹腔注射麻醉成功后,5%碘酒及75%的酒精局部消毒术区,于大鼠后背剪去直径4×4cm的皮毛,硫化钠脱毛处理,龙胆紫在脱毛区标记后,用外科方法在大鼠背部以脊柱为中线制备约2.0cm×2.0cm的圆形全层皮肤溃疡模型,每日用冰醋酸涂创面一次,5cm×7cm 4层纱布块包扎固定,1周后形成缺损性皮肤大鼠模型。
2.实验动物分组
48只皮肤溃疡大鼠随机分为:
(1)空白对照组
(2)次氯酸温敏凝胶组(实验组)
(3)皮肤溃疡模型组(模型组)
(4)皮肤溃疡阳性组(康复新液)
3.给药方法
实验组每日局部消毒后创面均匀喷洒次氯酸温敏凝胶;对照组局部消毒后予康复新液均匀喷于创面,以浸湿创面为准,每日一次。模型组每日用生理盐水清洗创面。空白对照组每日给与生理盐水涂抹背部
4.观察指标
造模后及观察结束时(分别按各组所规定时间)计算创面愈合率,
收缩率=(原有面积-未愈合创面面积)/创面原有面积×100%
5.实验结果
表1各组大鼠给药前后创面面积及收缩率
模型组创面收缩率为38.81%,与模型组相比,阳性对照组中大鼠皮肤创面收缩率83.36%;次氯酸温敏凝胶组收缩率最高82.36%。
Claims (7)
1.一种具有生理响应性的次氯酸凝胶,其特征在于,包括:
a)创面修复材料,透明质酸钠和/或透明质酸衍生物;
b)抑菌成分,次氯酸和/或次氯酸盐;
c)温敏性基质材料,由泊洛沙姆407和/或泊洛沙姆188组成;
d)pH缓冲剂包括氯化钠、氯化钾、硫酸、盐酸、磷酸、磷酸盐或其他可溶性盐;
e)溶剂,纯化水。
所述的具有生理响应性的次氯酸凝胶中,透明质酸钠的质量浓度(w/v)≤1%,泊洛沙姆407的质量浓度(w/v)为17%~21%,泊洛沙姆188的质量浓度(w/v)为1%-3%,次氯酸的质量浓度(w/v)为0.01%-0-2.00%。
2.如权利要求1所述的具有生理响应性的次氯酸凝胶,其特征在于,所述的具有生理响应性的次氯酸凝胶中还添加药剂学上可接受的药用辅料。
3.如权利要求2所述的具有生理响应性的次氯酸凝胶,其特征在于,所述药用辅料包括黏度调节剂、助悬剂、抗氧剂、稳定剂和保湿剂中的一种或几种。
4.如权利要求1所述的具有生理响应性的次氯酸凝胶,其特征在于,所述水为注射用水、生理盐水或纯化水。
5.如权利要求1所述的具有生理响应性的次氯酸凝胶,其特征在于,所述透明质酸钠衍生物为透明质酸钠交联聚合物、透明质酸酯或透明质酸金属盐。
6.如权利要求1所述的具有生理响应性的次氯酸凝胶,其特征在于,所述具有生理响应性的次氯酸凝胶的胶凝温度在30-37℃之间。
7.权利要求1所述的具有生理响应性的次氯酸凝胶在治疗皮肤创面的临床试验中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011070468.XA CN111991417A (zh) | 2020-10-06 | 2020-10-06 | 一种具有生理响应性的次氯酸凝胶及其在皮肤创面中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011070468.XA CN111991417A (zh) | 2020-10-06 | 2020-10-06 | 一种具有生理响应性的次氯酸凝胶及其在皮肤创面中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111991417A true CN111991417A (zh) | 2020-11-27 |
Family
ID=73475679
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011070468.XA Pending CN111991417A (zh) | 2020-10-06 | 2020-10-06 | 一种具有生理响应性的次氯酸凝胶及其在皮肤创面中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111991417A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111603399A (zh) * | 2020-06-28 | 2020-09-01 | 南京东万生物技术有限公司 | 一种口腔含漱液及其制备方法 |
CN113082050A (zh) * | 2021-04-26 | 2021-07-09 | 贵州扬生医用器材有限公司 | 一种妇科用温敏凝胶及其制备方法 |
-
2020
- 2020-10-06 CN CN202011070468.XA patent/CN111991417A/zh active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111603399A (zh) * | 2020-06-28 | 2020-09-01 | 南京东万生物技术有限公司 | 一种口腔含漱液及其制备方法 |
CN113082050A (zh) * | 2021-04-26 | 2021-07-09 | 贵州扬生医用器材有限公司 | 一种妇科用温敏凝胶及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110448722B (zh) | 一种可注射含单宁酸的温敏复合抗菌水凝胶材料及其制备和应用 | |
WO2019091150A1 (zh) | 一种藻酸盐创面修复敷料及其制备方法 | |
US6348190B1 (en) | Pharmaceutical compositions with antimicrobial activity | |
CN108187132A (zh) | 一种聚维酮碘水凝胶抗菌敷料及其制备方法 | |
CN104307032A (zh) | 一种止痛、抗菌、止血并促进伤口愈合的液体敷料 | |
CN110740723A (zh) | 含壳聚糖调配物及其制备和使用方法 | |
CN105168238A (zh) | 一种透明质酸温敏凝胶及其制备方法和应用 | |
WO2017215610A1 (zh) | 一种高效安全的壳聚糖衍生物基消毒液及其制备方法 | |
CN109010124B (zh) | 一种海洋精粹妇科抑菌凝胶及其制备方法 | |
CN111991417A (zh) | 一种具有生理响应性的次氯酸凝胶及其在皮肤创面中的应用 | |
CN110859989B (zh) | 一种液体创可贴及其制备方法 | |
CN114652767B (zh) | 一种奶牛乳头药浴剂及其制备方法 | |
CN105169455A (zh) | 一种烧烫伤外用急救医用敷料及其制备方法 | |
CN101716186A (zh) | 一种伤口抗菌冲洗液及其制备方法 | |
CN112438964A (zh) | 一种溶葡萄球菌酶与壳聚糖复合抗菌喷膜剂 | |
US8568711B2 (en) | Antimicrobial compositions | |
CN104095876A (zh) | 一种稳定的医用防护冲洗液及其制备方法 | |
JP2002104974A (ja) | ハイドロゲル損傷皮膚治療剤 | |
CN110198731B (zh) | 包含二巯基丙磺酸钠和二甲亚砜的抗菌剂组合物、所述组合物的用途和使用其的伤口处理方法 | |
CN102526121B (zh) | 一种创面修复组合物及其制备方法和用途 | |
CN108096276A (zh) | 一种清创愈合洗液及其应用 | |
KR102503193B1 (ko) | 버섯 또는 진균 유래 키토산, 또는 그 유도체를 이용한 하이드로겔 및 그 제조방법 | |
RU2404751C2 (ru) | Ранозаживляющее средство | |
CN114522268B (zh) | 一种皮肤修复材料及其制备方法和应用 | |
CN112274690B (zh) | 一种液体敷料及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20201127 |